Sentences with phrase «vaccine efficacy trial»

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.

Randomized, Double - Blind Evaluation of Late Boost Strategies for HIV - Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Not exact matches

Most biotechs would have shuttered a clinical program that showed absolutely no efficacy whatsoever in a late - stage trial, but Novavax has instead doubled down on RSV by going forth with its phase 3 trial of the RSV F vaccine for infants via maternal immunization, and begun planning for another trial in older adults that's reportedly on track to kick off in 2018.

«Obviously one would want to have a higher efficacy when it comes to severe disease, but we're still hoping we can improve on the vaccine as we go along with the trials.»

More than 5,000 people in Guinea received the vaccine in a trial to gauge its efficacy.

The company plans in October to conduct a separate test specifically to study the seasonal flu vaccine's effectiveness among 480 elderly participants (a demographic often encouraged to get seasonal flu shots), and Phase III efficacy trials across a larger set of demographics are scheduled to begin early next year.

And scientists who conduct human challenge studies, which typically involve a few dozen participants, say they have critical benefits: In addition to saving time and money, they can reveal harm caused by a potential drug or vaccine before it enters large - scale human efficacy trials.

The mosquito - borne disease caused by the Plasmodium parasite kills more than 700,000 people every year, the vast majority of them African children, and no vaccine has ever shown efficacy in trials.

Human safety trials for a vaccine to jump - start immunity could begin later this year; larger efficacy trials may be a year and a half away.

[NIAID Director Anthony] Fauci says $ 56 million of the total would go toward a larger efficacy trial in Liberia, which would include both the NIAID / GSK [GlaxoSmithKline] vaccine and another made by NewLink Genetics of Ames, Iowa (pending more data from ongoing safety trials).»

The extent of the benefit, she acknowledged, is not yet clear because the trial did not measure the vaccine's efficacy in preventing cancers.

The data obtained from this study provide a basis for more rapid, cost - effective clinical trials to evaluate new influenza drugs or to determine the efficacy of candidate vaccines for both seasonal and pandemic influenza.

Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees.

Vaccine efficacy was set at an average of 60 % (actual numbers depended on the different virus subtypes and on whether a person had been exposed due to a prior natural infection) based on recent phase III trial results for the Sanofi - Pasteur vaccine that had shown moderate effectiVaccine efficacy was set at an average of 60 % (actual numbers depended on the different virus subtypes and on whether a person had been exposed due to a prior natural infection) based on recent phase III trial results for the Sanofi - Pasteur vaccine that had shown moderate effectivaccine that had shown moderate effectiveness.

Antibody action Only an efficacy trial involving people at risk of infection can reveal whether a vaccine prevents infection.

Based in part on these results, the Butantan Institute in São Paulo, Brazil, this year launched an efficacy trial of the vaccine that plans to enroll 17,000 people.

Efficacy trials may test both vaccines simultaneously.

In a few weeks, meeting participants learned, enough data may be available from small phase I trials of a vaccine jointly made by the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline (GSK) that began in September to launch efficacy studies.

The DarDar Trial remains the only trial in which a new tuberculosis vaccine has shown efficacy in huTrial remains the only trial in which a new tuberculosis vaccine has shown efficacy in hutrial in which a new tuberculosis vaccine has shown efficacy in humans.

The trial is sponsored by Global Health Innovative Technology Fund (Japan) and results of vaccine efficacy will be available in late 2018.

At the meeting, GlaxoSmithKline (GSK) of Rixensart, Belgium, which has the vaccine furthest in development, spelled out how it might scale up production in parallel with the safety and efficacy trials now under way so that the product could be ready for wider distribution by April if warranted.

As a result, the trial can not evaluate the vaccine's efficacy.

White MT, Verity R, Griffin JT, et al.White MT, Verity R, Griffin JT, Asante KP, Owusu - Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC close, 2015, Immunogenicity of the RTS, S / AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infectious Diseases, Vol: 15, ISSN: 1473 - 3099, Pages: 1450 - 1458

SEATTLE, WA and DURHAM, NC — The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) today announced the initiation of HVTN 704 / HPTN 085, also known as Antibody Mediated Prevention (AMP) or the AMP Study, a Phase 2b clinical trial to evaluate the safety and efficacy of VRC01, a broadly neutralizing monoclonal antibody (bnAb).

The HVTN is an international collaboration that conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy.

Because the H10N8 and H7N9 strains are not circulating in the general population where the trials are taking place (the U.S. and Germany), Moderna is able to study the efficacy of its vaccine technology in naïve patient populations.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, the efficacy at 3.5 - years was 31.2 %; however, a higher early effect (60 %) was seen at 12 months.

A new paper published in the Journal of Allergy and Clinical Immunology has reported on a multicentre trial to test the safety and clinical efficacy of a new vaccine against grass pollen allergy in patients with grass pollen — induced rhinitis and controlled asthma.

Writing in The Lancet journal, a research team has published the results of a trial of an Ebola vaccine developed by the Public Health Agency of Canada and Merck, reporting 100 % efficacy.

As AMA1 malaria vaccines are evaluated in efficacy trials, the impact of genetic diversity of parasite antigens on vaccine efficacy is likely to emerge as a critical problem requiring integration of methods and concepts drawn from molecular epidemiology, molecular evolution, immunology and structural vaccinology [9], [13].

The development track will begin with a Phase I trial to test the vaccine regimen's safety and immunogenicity and depending on those study results, a larger efficacy study will follow.

«Successful antagonists, following clinical trials for safety and efficacy, could be incorporated into the seasonal vaccine as a way of enhancing responses.

The World Health Organisation has announced that a phase III trial of the VSV - EBOV vaccine will begin in Guinea on the 7th March, to test its efficacy against Ebola.

This malaria vaccine is being evaluated in a Phase 2 efficacy trial in children at this site.

PD01A: Promising Animal Efficacy; Initial Human Safety and Hints of Disease Modification At the time of our last post on α - synuclein vaccines, AFFiRiS had published several papers about the AFFITOME immnotherapy discovery platform [8 - 11] and had even begun their first Phase I trial of PD01A, but had kept nearly silent on many of the most elementary aspects of the vaccine.

Its Clinical Trials Center conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea last year.

He also oversaw the licensure, under accelerated approval, of a new high - dose formulation of an influenza vaccine, which demonstrated superior efficacy to conventional vaccines in clinical trials.

We are in the midst of an unprecedented time in HIV vaccine research; we have four concurrent efficacy trials underway, which will collectively enroll 12,200 volunteers in the search for an HIV vaccine over the next few years.

«This finding is consistent with a hypothesis generated out of the follow - up studies to the RV144 HIV vaccine trial in Thailand that showed the first efficacy in humans,» noted COL Nelson Michael, Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

It played a critical role landmark RV144 «Thai Study,» a 16,000 person study which was the only HIV vaccine trial to date to demonstrate modest (31 %) efficacy of a potential HIV vaccine, and the follow - on studies on the RV144 correlates of risk.

When a clinical trial of a vaccine begins, scientists hope that the study will add useful information about the efficacy of the vaccine and its mechanism of action.

«This study allowed us to evaluate the protective efficacy of several prime - boost vaccine combinations, and these data will help guide the advancement of the most promising candidates into clinical trials,» noted lead author Dr. Dan Barouch of Beth Israel Deaconess Medical Center at Harvard Medical School and the Ragon Institute of MGH, MIT, and Harvard.

Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pVaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pvaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.

At the first plenary session of AIDS Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infVaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infvaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.

The same year, the FDA approved the start of the first human clinical trial of this vaccine that demonstrated its safety and efficacy at inducing an immune response against the virus.

Picker explained that clinical trials are gearing up to test the safety and efficacy of a human version of the vaccine.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.

MHRP is proud to have led a large group that executed the landmark RV144 vaccine trial, the first study to show efficacy in preventing HIV infection.

In addition, the Fletcher group investigates immunity using the mouse model and aims to develop animal models of TB disease better able to predict TB vaccine efficacy in clinical trials.

A good knowledge of correlates of protection could predict the efficacy of novel vaccines at early stages of development and help identify the most promising candidates for vaccine trials.